Key result
Indobufen completely inhibits ex vivo secondary platelet aggregation and thromboxane B2 production in healthy volunteers.
Why the study?
Does indobufen inhibit platelet aggregation, the release reaction, and thromboxane B2 production in normal volunteers?
Population
8 normal volunteers
Design
Preclinical
Follow-up
2 hours
Authors
Loading...
Indobufen inhibits platelet function ex vivo in volunteers; hypothesis-generating for antithrombotic effects, requiring clinical outcome trials.
Does indobufen inhibit platelet aggregation, the release reaction, and thromboxane B2 production in normal volunteers?
Indobufen effectively inhibits platelet aggregation and the release reaction by blocking the platelet arachidonate pathway.
Cattaneo et al. (2009) studied Healthy volunteers (n=8). Indobufen was evaluated on Platelet aggregation, release reaction and thromboxane B2 production. Indobufen (200 mg) completely inhibited secondary platelet aggregation, the release reaction, and thromboxane B2 production ex vivo in 8 normal volunteers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: